Takeda Pharmaceutical Company Limited (TAK)
USD 13.11
(-1.87%)
USD 13.11
(-1.87%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 2618.18 Billion JPY | 14.19% |
| 2023 | 2292.9 Billion JPY | 14.57% |
| 2022 | 2001.31 Billion JPY | 18.12% |
| 2021 | 1694.23 Billion JPY | -19.36% |
| 2020 | 2101.01 Billion JPY | 64.51% |
| 2019 | 1277.16 Billion JPY | 23.66% |
| 2018 | 1032.82 Billion JPY | 1.51% |
| 2017 | 1017.42 Billion JPY | -10.84% |
| 2016 | 1141.14 Billion JPY | -17.67% |
| 2015 | 1386.08 Billion JPY | 30.5% |
| 2014 | 1062.14 Billion JPY | 7.6% |
| 2013 | 987.13 Billion JPY | 21.76% |
| 2012 | 810.71 Billion JPY | 10.34% |
| 2011 | 734.71 Billion JPY | -3.41% |
| 2010 | 760.69 Billion JPY | -19.28% |
| 2009 | 942.32 Billion JPY | 40.01% |
| 2008 | 673.04 Billion JPY | 18.7% |
| 2007 | 567 Billion JPY | 7.53% |
| 2006 | 527.29 Billion JPY | 15.0% |
| 2005 | 458.5 Billion JPY | 2.94% |
| 2004 | 445.4 Billion JPY | 2.38% |
| 2003 | 435.05 Billion JPY | 12.72% |
| 2002 | 385.96 Billion JPY | 9.23% |
| 2001 | 353.36 Billion JPY | 10.65% |
| 2000 | 319.35 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 568.93 Billion JPY | -8.85% |
| 2024 Q3 | 665.29 Billion JPY | -11.16% |
| 2024 FY | 1794.79 Billion JPY | -21.72% |
| 2024 Q4 | 481.09 Billion JPY | -27.69% |
| 2024 Q2 | 748.85 Billion JPY | 1.22% |
| 2023 Q1 | 529.06 Billion JPY | -6.61% |
| 2023 Q3 | 613.58 Billion JPY | 3.57% |
| 2023 FY | 2292.9 Billion JPY | 14.57% |
| 2023 Q4 | 557.82 Billion JPY | -9.09% |
| 2023 Q2 | 592.42 Billion JPY | 11.98% |
| 2022 FY | 2001.31 Billion JPY | 18.12% |
| 2022 Q3 | 503.4 Billion JPY | 6.75% |
| 2022 Q1 | 459.78 Billion JPY | 25.53% |
| 2022 Q4 | 566.52 Billion JPY | 12.54% |
| 2022 Q2 | 471.59 Billion JPY | 2.57% |
| 2021 Q2 | 490.99 Billion JPY | 23.84% |
| 2021 Q3 | 440.47 Billion JPY | -10.29% |
| 2021 Q4 | 366.28 Billion JPY | -16.84% |
| 2021 FY | 1694.23 Billion JPY | -19.36% |
| 2021 Q1 | 396.48 Billion JPY | -32.3% |
| 2020 Q1 | 538.66 Billion JPY | -2.32% |
| 2020 Q3 | 526.23 Billion JPY | 5.48% |
| 2020 Q4 | 585.65 Billion JPY | 11.29% |
| 2020 FY | 2101.01 Billion JPY | 64.51% |
| 2020 Q2 | 498.89 Billion JPY | -7.38% |
| 2019 Q3 | 248.42 Billion JPY | 0.6% |
| 2019 Q4 | 551.43 Billion JPY | 121.97% |
| 2019 FY | 1277.16 Billion JPY | 23.66% |
| 2019 Q2 | 246.94 Billion JPY | 7.19% |
| 2019 Q1 | 230.37 Billion JPY | -37.83% |
| 2018 Q2 | 271.92 Billion JPY | 105.39% |
| 2018 FY | 1032.82 Billion JPY | 1.51% |
| 2018 Q4 | 370.56 Billion JPY | 43.67% |
| 2018 Q3 | 257.92 Billion JPY | -5.15% |
| 2018 Q1 | 132.39 Billion JPY | -61.44% |
| 2017 Q1 | 145.67 Billion JPY | -54.16% |
| 2017 FY | 1017.42 Billion JPY | -10.84% |
| 2017 Q4 | 343.36 Billion JPY | 30.95% |
| 2017 Q3 | 262.2 Billion JPY | -1.5% |
| 2017 Q2 | 266.19 Billion JPY | 82.73% |
| 2016 Q1 | 275.61 Billion JPY | -56.36% |
| 2016 FY | 1141.14 Billion JPY | -17.67% |
| 2016 Q3 | 287.15 Billion JPY | 10.2% |
| 2016 Q2 | 260.57 Billion JPY | -5.46% |
| 2016 Q4 | 317.8 Billion JPY | 10.68% |
| 2015 Q3 | 266.85 Billion JPY | 3.33% |
| 2015 FY | 1386.08 Billion JPY | 30.5% |
| 2015 Q4 | 631.56 Billion JPY | 136.67% |
| 2015 Q2 | 258.24 Billion JPY | 12.57% |
| 2015 Q1 | 229.42 Billion JPY | -24.52% |
| 2014 Q2 | 244.89 Billion JPY | -1.05% |
| 2014 Q3 | 260.49 Billion JPY | 6.37% |
| 2014 Q4 | 303.95 Billion JPY | 16.68% |
| 2014 FY | 1062.14 Billion JPY | 7.6% |
| 2014 Q1 | 247.5 Billion JPY | -13.23% |
| 2013 Q4 | 285.25 Billion JPY | -47.87% |
| 2013 FY | 987.13 Billion JPY | 21.76% |
| 2013 Q1 | 78.87 Billion JPY | -87.3% |
| 2013 Q2 | 75.79 Billion JPY | -3.9% |
| 2013 Q3 | 547.2 Billion JPY | 621.91% |
| 2012 Q1 | 57.71 Billion JPY | -89.4% |
| 2012 Q4 | 620.97 Billion JPY | 777.86% |
| 2012 Q3 | 70.73 Billion JPY | 15.42% |
| 2012 Q2 | 61.28 Billion JPY | 6.19% |
| 2012 FY | 810.71 Billion JPY | 10.34% |
| 2011 Q4 | 544.71 Billion JPY | 727.76% |
| 2011 Q1 | 62.11 Billion JPY | -88.74% |
| 2011 Q2 | 62.08 Billion JPY | -0.05% |
| 2011 Q3 | 65.8 Billion JPY | 6.0% |
| 2011 FY | 734.71 Billion JPY | -3.41% |
| 2010 FY | 760.69 Billion JPY | -19.28% |
| 2010 Q3 | 73.69 Billion JPY | 4.22% |
| 2010 Q2 | 70.71 Billion JPY | 9.01% |
| 2010 Q4 | 551.41 Billion JPY | 648.2% |
| 2010 Q1 | 64.86 Billion JPY | -88.51% |
| 2009 Q4 | 564.72 Billion JPY | 898.97% |
| 2009 FY | 942.32 Billion JPY | 40.01% |
| 2009 Q2 | 86.23 Billion JPY | 0.0% |
| 2009 Q3 | 56.53 Billion JPY | -34.45% |
| 2008 FY | 673.04 Billion JPY | 18.7% |
| 2007 FY | 567 Billion JPY | 7.53% |
| 2006 FY | 527.29 Billion JPY | 15.0% |
| 2005 FY | 458.5 Billion JPY | 2.94% |
| 2004 FY | 445.4 Billion JPY | 2.38% |
| 2003 FY | 435.05 Billion JPY | 12.72% |
| 2002 FY | 385.96 Billion JPY | 9.23% |
| 2001 FY | 353.36 Billion JPY | 10.65% |
| 2000 FY | 319.35 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 616.19 Million USD | -424797.8% |
| Bausch Health Companies Inc. | 5.23 Billion USD | -49913.028% |
| Catalent, Inc. | 1.7 Billion USD | -153729.73% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -250683.716% |
| Elanco Animal Health Incorporated | 1.61 Billion USD | -162318.238% |
| Perrigo Company plc | 1.52 Billion USD | -171190.939% |
| Teva Pharmaceutical Industries Limited | 4.45 Billion USD | -58722.332% |
| Zoetis Inc. | 2.76 Billion USD | -94590.127% |